Ubi Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services.

Employees

Sector

Pharmaceuticals

More about the company

End-of-day quote Taipei Exchange 06/05/2024			5-day change	1st Jan Change
14.25 ^TWD	+1.79%		-.--%	-

13/08	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
27/04	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.68B 53.4M 45.91M 43.19M 39.42M 73.56M 5.06B 73.94M 512M 198M 2.59B 201M 196M 8.23B	P/E 2024	-9.63x	P/E 2025	-5.68x
Enterprise Value	1.97B 62.56M 53.79M 50.61M 46.18M 86.19M 5.93B 86.63M 600M 232M 3.03B 235M 230M 9.65B	EV / Sales 2024	3.58x	EV / Sales 2025	3.83x
Free-Float	27.79%	Yield 2024 *	-	Yield 2025	-

13/08	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
27/04	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/08/25	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/08/24	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/04/24	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/08/23	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
21/04/23	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/08/22	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
29/04/22	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
29/04/22	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/08/21	Medigen Vaccine Biologics : Taiwan rejects COVID vaccine candidate, president to get domestic shot	RE
16/08/21	Medigen Vaccine Biologics : Taiwan denies approval for UBI's COVID-19 vaccine candidate	RE

3 years	10	38.5
5 years	10	126.56
10 years	8.34	288.72

UBI Pharma Inc. Stock

Stocks

6562

TW0006562002

Pharmaceuticals

Valuation : UBI Pharma Inc.

Latest news : UBI Pharma Inc.

Quotes and Performance

Price Extremes

Managers and Directors : UBI Pharma Inc.

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Jung Kuang Yang CEO	Chief Executive Officer	-	-
Meng Han Hsu DFI	Director of Finance/CFO	-	11/04/2016
Ying Yun Fan ADM	Chief Administrative Officer	-	01/03/2015

Director	Title	Age	Since
Ying Yun Fan BRD	Director/Board Member	-	30/06/2020
Yan Ning Kuo BRD	Director/Board Member	-	30/06/2020
Yao Hui Wei BRD	Director/Board Member	-	30/06/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
UBI PHARMA INC.	+1.79%	-.--%	-.--%	-56.22%	53.35M
ELI LILLY AND COMPANY	-2.21%	-3.11%	+52.16%	+91.64%	1,024B
JOHNSON & JOHNSON	-2.22%	-0.76%	+51.08%	+67.61%	663B
ABBVIE INC.	-2.99%	-4.31%	+18.59%	+66.94%	453B
ROCHE HOLDING AG	-0.88%	+0.86%	+29.77%	+36.54%	349B
NOVARTIS AG	-10.89%	-14.63%	+9.27%	+26.87%	295B
ASTRAZENECA PLC	-1.38%	-0.72%	-0.79%	+9.50%	253B
AMGEN INC.	-10.08%	-10.26%	+40.32%	+51.55%	236B
NOVO NORDISK A/S	-2.32%	-0.65%	-15.84%	-56.91%	206B
GILEAD SCIENCES, INC.	-2.88%	-2.19%	+26.54%	+92.95%	187B
Average	-3.07%	+0.45%	+21.11%	+33.05%	366.74B
Weighted average by Cap.	-2.42%	-1.04%	+32.70%	+57.27%

	2024	2025
Net sales	539M 17.09M 14.7M 13.83M 12.62M 23.55M 1.62B 23.67M 164M 63.38M 828M 64.19M 62.79M 2.64B	514M 16.32M 14.03M 13.2M 12.05M 22.48M 1.55B 22.6M 156M 60.51M 791M 61.28M 59.94M 2.52B
Net income	-175M -5.54M -4.76M -4.48M -4.09M -7.63M -525M -7.67M -53.06M -20.53M -268M -20.79M -20.34M -854M	-296M -9.4M -8.08M -7.6M -6.94M -12.95M -891M -13.02M -90.08M -34.85M -455M -35.29M -34.52M -1.45B
Net Debt	246M 7.82M 6.72M 6.32M 5.77M 10.77M 741M 10.82M 74.9M 28.98M 379M 29.35M 28.71M 1.21B	289M 9.16M 7.88M 7.41M 6.77M 12.63M 869M 12.69M 87.84M 33.98M 444M 34.41M 33.66M 1.41B